Gufic Biosciences Limited has informed the Exchange about Investor Presentation
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences reported Q1 FY26 revenue of Rs. 226.9 crores, up ~12% YoY from Rs. 202.8 crores, but profitability came under significant pressure. EBITDA fell to Rs. 33.2 crores (margin of 14.63%) versus Rs. 37 crores (18.24%) in Q1 FY25, and PAT dropped to Rs. 12.1 crores from Rs. 20.9 crores, with PAT margins halving to 5.33%. The new Indore lyophilized injectables facility, capitalized in Q3 FY25, is on track for 30% capacity utilization and EBITDA breakeven in FY26, with management guiding it to become margin accretive from FY27. Strong momentum was seen in the NeuroCare Botulinum Toxin business (value up 107% YoY, market share rising from 7% to 17%) and the international business, which secured 13 product/facility approvals across 5 countries and won a UK NHS supply contract.
Shareholders will note a clear divergence: top-line growth remains healthy, but Q1 margins and profits have been hit by the Indore ramp-up costs, near-term dilution. However, the long-term story looks intact with a structured 3-5 year roadmap, growing CDMO and international pipelines, and an oncology platform (Selvax) in development.